tailieunhanh - Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: A systematic review and metaanalysis

Cardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addressed. The aim of this study was to assess the correlation between risk of CVEs and AIs in patients with breast cancer. | Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: A systematic review and metaanalysis

TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
24    133    1    26-11-2024
9    167    0    26-11-2024
22    147    2    26-11-2024